1.Study on the therapeutic effects of interferon and gamma-globulin in experimental Pneumocystis carinii pneumonia.
Dae Whan SHIN ; Dae Young KANG ; Young Ha LEE ; Young Eun NA ; Keon Jung YUN
The Korean Journal of Parasitology 1992;30(3):219-226
This study was performed to observe the therapeutic effects of interferon-gamma(IFN-gamma) and gamma-globulin(gamma-globulin) in experimental Pneumocystis carinii pneumonia of immune suppressed mice. After 9 weeks, trimethoprim-sulfamethoxazole(TMP-SMZ; 10-50 mg/mouse/day), mouse IFN-gamma(5 x 10(4) units/mouse/day) and mouse gamma-globulin(20 mg/mouse/day) were administered to the mice for 3 weeks by the experimental group. The therapeutic efficacy was evaluated by body weights, histopathologic and electron microscopic findings of the lungs, and number of P. carinii cysts by Gomori's methenamine silver stain. Body weights of the mice were significantly increased in the group of combination therapy of TMP-SMZ with IFN-gamma or gamma-globulin, and in the group of TMP-SMZ treatment (p < 0.05), however, little effect was found in the group of gamma-globulin alone. Histopathologic findings of P. carinii pneumonia were much improved in the group of combination therapy of TMP-SMZ with IFN-gamma. Treatment with either TMP-SMZ or IFN-gamma significantly reduced the number of cysts in the P. carinii pneumonia, but gamma-globulin alone was ineffective. In electron microscopic findings of P. carinii pneumonia, the number of trophozoites and cysts were reduced by treatment with either TMP-SMZ or IFN-gamma, and most of the cysts were empty or containing one or two intracystic bodies. The present results suggested, that combination therapy of TMP-SMZ with IFN-gamma had synergistic effects in treatment of P. carinii pneumonia in experimental mice.
Drug-Synergism
;
Drug-Therapy,-Combination
;
English-Abstract
;
Gamma-Globulins-administration-and-dosage
;
Interferon-Type-II-administration-and-dosage
;
Mice-
;
Trimethoprim-Sulfamethoxazole-Combination-administration-and-dosage
;
*Gamma-Globulins-therapeutic-use
;
*Interferon-Type-II-therapeutic-use
;
*Pneumonia,-Pneumocystis-carinii-therapy
;
Gamma-Globulins
;
Trimethoprim-Sulfamethoxazole-Combination
;
Interferon-Type-II
2.The necessity of diet therapy for successful interferon-gamma therapy in atopic dermatitis.
Sang Sun LEE ; Ki Young LEE ; Geunwoong NOH
Yonsei Medical Journal 2001;42(2):161-171
The avoidance of incriminated foods is one of the principal therapies for atopic dermatitis (AD). Recently, interferon (IFN)-gamma therapy has been tried in AD with limited success. The necessity of diet therapy for the success of IFN-gamma therapy in AD was evaluated. A total of 524 AD patients participated in this study and 316 patients among them were entered into open food challenge tests. As the first step, an elimination diet was administered to 43 AD patients and 30 AD patients were enrolled as an untreated control group. As the second step, 45 AD patients were treated by both IFN-gamma therapy and elimination diet alone, 30 AD patients by elimination diet alone, 50 AD patients by IFN-gamma therapy, and 43 AD patients as controls. Clinical severity reduced significantly by using only the elimination diet in 58.1% patients with varying degrees of AD. Elimination diet improved the clinical results of IFN-gamma therapy in AD. In regard to the food challenge test, 77.8% of AD patients showed an adverse reaction to at least one food. Diet therapy itself had therapeutic effects on AD and an elimination diet might be essential for the success of IFN-gamma therapy in AD.
Adolescence
;
Adult
;
Child
;
Child, Preschool
;
Dermatitis, Atopic/drug therapy*
;
Dermatitis, Atopic/diet therapy*
;
Female
;
Food Hypersensitivity/diet therapy
;
Human
;
Interferon Type II/therapeutic use*
;
Male
;
Treatment Outcome
3.Six-month Therapy with Aerosolized Interferon-gamma for Refractory Multidrug-Resistant Pulmonary Tuberculosis.
Won Jung KOH ; O Jung KWON ; Gee Young SUH ; Man Pyo CHUNG ; Hojoong KIM ; Nam Yong LEE ; Tae Sung KIM ; Kyung Soo LEE
Journal of Korean Medical Science 2004;19(2):167-171
The aim of this study was to investigate the adjuvant effects of interferon-gamma (IFN-gamma) inhalation therapy for six months in the treatment of refractory multidrug-resistant pulmonary tuberculosis (MDR-TB). Aerosolized IFN-gamma was given to six MDRTB patients with persistent positive smears and cultures despite long-term medical treatment. The patients received aerosolized two million international units of IFNthree times a week for 6 months while they continued on identical antituberculous chemotherapy. Before IFN-gamma inhalation therapy, the patients received a median of 6.5 (range, 4 to 7) antituberculous drugs for median duration of 29 months (range,7 to 76). After IFN-gamma inhalation therapy, sputum smears remained persistently positive in all patients throughout the study period. Sputum cultures were transiently negative at the 4th month in two patients, but became positive again at the end of 6 months of IFN-gamma therapy. Five patients had radiological improvement including three patients who showed a decrease in the size of the cavitary lesions. Resectional surgery could be performed in one patient in whom substantial clinical and radiological improvement was noted after IFN-gamma inhalation therapy. These results suggest that IFN-gamma inhalation therapy may be effective for some cases of refractory MDR-TB who are otherwise not responding to conventional therapy.
Administration, Inhalation
;
Adult
;
Antineoplastic Agents/*administration & dosage
;
Antitubercular Agents/therapeutic use
;
Drug Resistance, Bacterial
;
Drug Resistance, Multiple
;
Drug Therapy, Combination
;
Female
;
Human
;
Interferon Type II/*administration & dosage
;
Male
;
Middle Aged
;
Support, Non-U.S. Gov't
;
Tuberculosis, Pulmonary/*drug therapy/radiography
4.Ovalbumin fused with diphtheria toxin protects mice from ovalbumin induced anaphylactic shock.
Bong Ki LEE ; Young Gun YOO ; Won Young LEE ; Chun Soo HONG ; Jae Ku PARK ; Jai Youl RO
Yonsei Medical Journal 2001;42(1):91-105
For those with allergy, vaccination with a specific allergen has often been used as a major therapeutic measure. However, the universal application of this technique in clinics have been restricted due to its low success rates and the risk of active systemic anaphylactic shock (ASAS). In this regard, we constructed a fusion protein (OVA-DT), ovalbumin (OVA) fused with diphtheria toxin protein (DT), which may exert a specific cytotoxicity to cells bearing OVA-specific IgE. Its therapeutic effect was evaluated in mice (BALB/c) sensitized with OVA (Os-mice). OVA challenges to the OVA-sensitized mice (Os-mice) caused ASAS to death within 30 min, but OVA-DT treatment afforded mice complete protection. When OVA-DT was treated to the Os-mice, none showed the signs of ASAS when re-challenged 48 h after the treatment. OVA-DT itself was not found to be toxic or allergenic in normal mice. The effect of OVA-DT on the biological functions of mast cells was also studied. Binding of OVA-DT to OVA-specific IgE bearing mast cells and the inhibition of histamine release from these cells were observed. In addition, OVA-DT treatment inhibited the proliferation of OVA-specific B cells in mice. In Os-mice treated with OVA-DT, levels of anti-OVA IgG2a in serum and the production of IFN-gamma by splenic lymphocytes were found to increase, but the production of IL-4 by these cells decreased. Re-direction of cytokine profiles from OVA-specific Th2 to OVA-specific Thl is suggested. These results indicate that OVA-DT can protect Os-mice from ASAS due to OVA challenge, because it inactivates OVA-specific IgE-expressing cells, including mast cells and B cells.
Anaphylaxis/prevention | control*
;
Animal
;
B-Lymphocytes/immunology
;
Female
;
Histamine Release/drug effects
;
IgE/metabolism
;
Interferon Type II/biosynthesis
;
Interleukin-4/biosynthesis
;
Lymphocyte Transformation/drug effects
;
Mast Cells/metabolism
;
Mice
;
Mice, Inbred BALB C
;
Ovalbumin/immunology*
;
Recombinant Fusion Proteins/therapeutic use*
5.Pleurotus nebrodensis polysaccharide (PN-S) enhances the immunity of immunosuppressed mice.
Hai-Yan CUI ; Chang-Lu WANG ; Yu-Rong WANG ; Zhen-Jing LI ; Mian-Hua CHEN ; Feng-Juan LI ; Yan-Ping SUN
Chinese Journal of Natural Medicines (English Ed.) 2015;13(10):760-766
In the present study, the effects of Pleurotus nebrodensis polysaccharide (PN-S) on the immune functions of immunosuppressed mice were determined. The immunosuppressed mouse model was established by treating the mice with cyclophosphamide (40 mg/kg/2d, CY) through intraperitoneal injection. The results showed that PN-S administration significantly reversed the CY-induced weight loss, increased the thymic and splenic indices, and promoted proliferation of T lymphocyte, B lymphocyte, and macrophages. PN-S also enhanced the activity of natural killer cells and increased the immunoglobulin M (IgM) and immunoglobulin G (IgG) levels in the serum. In addition, PN-S treatment significantly increased the phagocytic activity of mouse peritoneal macrophages. PN-S also increased the levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), interferon-γ (INF-γ), and nitric oxide (NOS) in splenocytes. qRT-PCR results also indicated that PN-S increased the mRNA expression of IL-6, TNF-α, INF-γ, and nitric oxide synthase (iNOS) in the splenocytes. These results suggest that PN-S treatment enhances the immune function of immunosuppressed mice. This study may provide a basis for the application of this fungus in adjacent immunopotentiating therapy against cancer and in the treatment of chemotherapy-induced immunosuppression.
Animals
;
Antineoplastic Agents, Alkylating
;
Biological Products
;
pharmacology
;
therapeutic use
;
Cell Line
;
Cyclophosphamide
;
Immunity
;
drug effects
;
Immunologic Factors
;
pharmacology
;
therapeutic use
;
Immunosuppression
;
Interferon-gamma
;
metabolism
;
Interleukin-6
;
metabolism
;
Macrophages
;
drug effects
;
metabolism
;
Male
;
Mice, Inbred BALB C
;
Neoplasms
;
drug therapy
;
immunology
;
Nitric Oxide
;
metabolism
;
Nitric Oxide Synthase Type II
;
metabolism
;
Phagocytosis
;
drug effects
;
Pleurotus
;
chemistry
;
Polysaccharides
;
pharmacology
;
therapeutic use
;
Tumor Necrosis Factor-alpha
;
metabolism
6.Effects of combined therapy with thalidomide and glucantime on leishmaniasis induced by Leishmania major in BALB/c mice.
Ghassem SOLGI ; Amina KARIMINIA ; Khossro ABDI ; Majid DARABI ; Behnaz GHAREGHOZLOO
The Korean Journal of Parasitology 2006;44(1):55-61
For treating Leishmania major infection in BALB/c mice, we used thalidomide in conjunction with glucantime. Groups of mice were challenged with 5 x 10(3) metacyclic promastigotes of L. major subcutaneously. A week after the challenge, drug treatment was started and continued for 12 days. Thalidomide was orally administrated 30 mg/kg/day and glucantime was administrated intraperitoneally (200 mg/kg/day). It was shown that the combined therapy is more effective than single therapies with each one of the drugs since the foot pad swelling in the group of mice received thalidomide and glucantime was significantly decreased (0.9 +/- 0.2 mm) compared to mice treated with either glucantime, thalidomide, or carrier alone (1.2 +/- 0.25, 1.4 +/- 0.3, and 1.7 +/- 0.27 mm, respectively). Cytokine study showed that the effect of thalidomide was not dependent on IL-12; however, it up-regulated IFN-gamma and down-regulated IL-10 production. Conclusively, thalidomide seems promising as a conjunctive therapy with antimony in murine model of visceral leishmaniasis.
Time Factors
;
Thalidomide/pharmacology/*therapeutic use
;
Organometallic Compounds/pharmacology/*therapeutic use
;
Mice, Inbred BALB C
;
Mice
;
Meglumine/pharmacology/*therapeutic use
;
Leishmaniasis, Visceral/*drug therapy/immunology
;
Leishmania major/*drug effects
;
Interleukin-12/analysis/biosynthesis
;
Interleukin-10/analysis/biosynthesis
;
Interferon Type II/analysis/biosynthesis/drug effects
;
Immunosuppressive Agents/pharmacology/*therapeutic use
;
Female
;
Drug Therapy, Combination
;
Disease Progression
;
Disease Models, Animal
;
Cells, Cultured
;
Antiprotozoal Agents/pharmacology/*therapeutic use
;
Animals
7.Effects of oral administration of type II collagen on adjuvant arthritis in rats and its mechanisms.
Yongxiu HU ; Wenming ZHAO ; Xianjuan QIAN ; Liping ZHANG
Chinese Medical Journal 2003;116(2):284-287
OBJECTIVETo investigate the effects of oral administration of type II collagen (CII) on adjuvant arthritis (AA) in rats and its mechanisms, and to compare the effects of CII with those of the Chinese traditional medicine Tripterygium Polyglycoside administered similarly.
METHODSArthritis was induced in rats by immunization using Freund's complete adjuvant (FCA). After feeding rats either soluble CII or Tripterygium Polyglycoside, changes in degree of articular swelling and articular histological findings were observed in AA rats. Some correlative immunological indexes were measured, including delayed type hypersensitivity (DTH) reaction, anti-collagen and anti-Mycobacterium tuberculosis (MT) antibody in serum, and levels of IFN-gamma and TNF-alpha in articular steep in rats.
RESULTSOral administration of CII was able to alleviate both distinctly articular and general symptoms in AA rats, suppress synovium hyperplasia and inflammatory cells infiltration in arthrosis capsule. The effects brought about by CII were stronger than those by Tripterygium Polyglycoside. Oral administration of CII inhibited antigen-specific immune response, such as DTH and antibody reaction to CII. In addition, the expression of IFN-gamma and TNF-alpha in joints were locally downregulated.
CONCLUSIONSThe therapeutic effect of oral administration of CII is obvious on adjuvant arthritis in rats. Its remedial mechanisms are likely related to the downregulation of both IFN-gamma and TNF-alpha, and the suppression of cell immunity.
Administration, Oral ; Animals ; Antibodies ; blood ; Arthritis, Experimental ; drug therapy ; immunology ; Collagen Type II ; therapeutic use ; Hypersensitivity, Delayed ; prevention & control ; Immune Tolerance ; Interferon-gamma ; biosynthesis ; Male ; Mycobacterium tuberculosis ; immunology ; Phytotherapy ; Rats ; Rats, Sprague-Dawley ; Synovial Membrane ; pathology ; Tripterygium ; Tumor Necrosis Factor-alpha ; biosynthesis
8.Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination.
Aeyung KIM ; Young Woock NOH ; Kwang Dong KIM ; Yong Suk JANG ; Yong Kyung CHOE ; Jong Seok LIM
Experimental & Molecular Medicine 2004;36(5):428-443
Immunization with dendritic cells (DCs) pulsed with tumor antigen can activate tumor-specific cytotoxic T lymphocytes (CTL), which is responsible for tumor protection and regression. In this study, we examined whether DCs pulsed with necrotic tumor lysates can efficiently prevent malignant melanoma tumor cell metastasis to the lung. DCs derived from mouse bone marrow were found to produce remarkably elevated levels of IL-12 after being pulsed with the tumor lysates. Moreover, immunization with these DCs induced CTL activation and protected mice from metastasis development by intravenously inoculated tumor cells. In addition, these DCs activated NK cells in vitro in a contact-dependent manner, and induced NK activities in vivo. Furthermore, NK cell depletion before DC vaccination significantly reduced the tumor-specific CTL activity, IFN-g production, and IFN-gamma- inducible gene expression, and eventually interfered with the antitumor effect of tumor-pulsed DCs. Finally, similar findings with respect to NK cell dependency were obtained in the C57BL/ 6J-bg/bg mice, which have severe deficiency in cytolytic activity of NK cells. These data suggest that the antitumor effect elicited by DC vaccination, at least in a B16 melanoma model, requires the participation of both cytolytic NK and CD8+ T cells. The findings of this study would provide important data for the effective design of DC vaccines for cancer immunotherapy.
Animals
;
Antigen Presentation/immunology
;
CD8-Positive T-Lymphocytes/immunology
;
Cancer Vaccines/*therapeutic use
;
Cell Line, Tumor
;
Cytokines/biosynthesis/immunology
;
Dendritic Cells/immunology/*transplantation
;
Female
;
Interferon Type II/biosynthesis/immunology
;
Interleukin-12/biosynthesis/immunology
;
Killer Cells, Natural/*immunology
;
Lung Neoplasms/immunology/prevention & control/secondary
;
Lymphocyte Activation/immunology
;
Lymphocyte Depletion
;
Melanoma, Experimental/immunology/secondary/*therapy
;
Mice
;
Mice, Inbred C57BL
;
Monocyte Chemoattractant Proteins/biosynthesis/immunology
;
Research Support, Non-U.S. Gov't
;
T-Lymphocytes, Cytotoxic/immunology